Trial reportHepatology (Baltimore, Md.)2019
Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients.
Trial report in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Global research hotspots and trends of acute rejection after liver transplantation from 1988 to 2022: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- Pooled it
- Pooled it
- Effects ofOpen life sciences · 2025Article
- Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development.Antibodies (Basel, Switzerland) · 2024Review
- The effect of donor against recipient one-way HLA mismatch on liver transplantation outcomes from a multicenter registry analysis.Scientific reports · 2023Article
- European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- New insights into maladaptive vascular responses to donor specific HLA antibodies in organ transplantation.Frontiers in transplantation · 2023Review
- Evidence for Alloimmune Sinusoidal Injury inTransplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Incidence of acute rejection and patient survival in combined heart-liver transplantation.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2022Article
- Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes.Nature medicine · 2022Article
- Chronic rejection after liver transplantation: Opening the Pandora's box.World journal of gastroenterology · 2021Article
- Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?European journal of immunology · 2021Review
- A combination of the percentages of IFN-γJournal of translational medicine · 2021Article
- Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management.Hepatology (Baltimore, Md.) · 2021Article
- Intra-operative kinetics of anti-HLA antibody in simultaneous liver-kidney transplantation.Molecular genetics and metabolism reports · 2021Article
- Strategies for Liver Transplantation Tolerance.International journal of molecular sciences · 2021Review
- The Model for End-Stage Liver Disease Score and the Follow-Up Period Can Cause the Shift of Circulating Lymphocyte Subsets in Liver Transplant Recipients.Frontiers in medicine · 2021Article
- Association between longer hospitalization and development ofRenal failure · 2020Article
- Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies.Scientific reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
The development of human leukocyte antigen (HLA) donor-specific antibody/antibodies (DSA) is not well described in liver transplant (LT) patients undergoing immunosuppression (IS) withdrawal protocols despite the allograft risk associated with de novo DSA (dnDSA). We analyzed the development of dnDSA in 69 LT patients who received calcineurin inhibitor monotherapy and were enrolled in the ITN030ST study. Of these 69 patients, 40 stable patients were randomized to IS maintenance (n = 9) or IS minimization (n = 31). Nine of the 31 IS minimization patients achieved complete withdrawal and were free of IS. Among patients who achieved stable IS monotherapy 1 year after transplantation, the prevalence of dnDSA was 18.8%. Acute rejections and the biopsy-proven findings disqualifying patients from IS withdrawal attempt were factors associated with dnDSA development (P = 0.011 and P = 0.041, respectively). Among randomized patients, dnDSA prevalence was 51.7% after IS minimization and 66.7% in IS-free patients. dnDSA prevalence in patients on IS maintenance was 44.4%. dnDSA development during IS minimization was a risk factor for acute rejection (P = 0.015). The majority of dnDSA were against HLA-DQ antigens (78.7%). Conclusion. During the first year following transplantation, acute rejections increase the risk of developing dnDSA, so dnDSA positivity should be considered for IS withdrawal eligibility; during IS minimization, dnDSA development was associated with acute rejection, which prevented further IS withdrawal attempts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.